Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Leukemia · Relapsed Leukemia · Chronic Lymphocytic Leukemia · Relapsed Cancer · Refractory Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Contact: Study coordinator (Jennifer Brown, MD, PhD) · Jennifer_brown@dfci.harvard.edu · 617-632-5847
Contact: Principal Investigator (Jennifer Brown, MD, PhD)

Study leads

Jennifer Brown, MD, PhD
Principal Investigator
Dana-Farber Cancer Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

Blood Cancer · Leukemia

Abroad (travel likely)Recruiting

Boston, United States

Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects

COPD · Lung Cancer (NSCLC) · Leukemia

Abroad (travel likely)Recruiting

Bologna, Italy · Bologna, Italy

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.

Chronic Lymphocytic Leukemia · CLL · Mantle Cell Lymphoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Tampa, United States · Fort Wayne, United States

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Chronic Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE2

Duarte, United States · Atlanta, United States